Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer

Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA
Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer ( Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA )
31 May 2014

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Dr John Byrd - The Ohio State University, Columbus, USA
Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL ( Dr John Byrd - The Ohio State University, Columbus, USA )
31 May 2014

Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer

Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France
Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer ( Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France )
31 May 2014

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

Dr Maurice Pérol - Centre Léon Bérard, Lyon, France
Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC ( Dr Maurice Pérol - Centre Léon Bérard, Lyon, France )
31 May 2014

Cancer evasion of the immune system: the fundamentals

Prof Pedro Romero - Ludwig Institute for Cancer Research, Lausanne, Switzerland
Cancer evasion of the immune system: the fundamentals ( Prof Pedro Romero - Ludwig Institute for Cancer Research, Lausanne, Switzerland )
20 May 2014

Checkpoint blockade: a concept or already a reality?

Prof Paolo Ascierto - National Cancer Institute 'Foundazione G. Pascale', Naples, Italy
Checkpoint blockade: a concept or already a reality? ( Prof Paolo Ascierto - National Cancer Institute 'Foundazione G. Pascale', Naples, Italy )
20 May 2014

Myeloma genomics and Immuno-oncology

Prof Keith Stewart; Prof Gareth Morgan; Dr Leif L. Bergsagel; Prof Antonio Palumbo
Myeloma genomics and Immuno-oncology ( Prof Keith Stewart; Prof Gareth Morgan; Dr Leif L. Bergsagel; Prof Antonio Palumbo )
15 May 2014

Novel targets and immune based therapy in myeloma

Dr Kenneth Anderson; Prof Antonio Palumbo; Prof Gareth Morgan; Prof Jesús San Miguel
Novel targets and immune based therapy in myeloma ( Dr Kenneth Anderson; Prof Antonio Palumbo; Prof Gareth Morgan; Prof Jesús San Miguel )
15 May 2014

Upcoming trends in myeloma therapy

Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson
Upcoming trends in myeloma therapy ( Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson )
15 May 2014

Lecture: Current standard of care in advanced disease

Dr Wayne YH Chang - National Yang-Ming University Taipei, Taiwan
Lecture: Current standard of care in advanced disease ( Dr Wayne YH Chang - National Yang-Ming University Taipei, Taiwan )
12 May 2014

Lecture: Exploring the androgen signalling pathway in CRPC

Dr Paul de Souza - University of Western Sydney, New South Wales, Australia
Lecture: Exploring the androgen signalling pathway in CRPC ( Dr Paul de Souza - University of Western Sydney, New South Wales, Australia )
12 May 2014

Lecture: Clinical perspectives: Non-AR therapeutic targets in CRPC

Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany;
Lecture: Clinical perspectives: Non-AR therapeutic targets in CRPC ( Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany; )
12 May 2014